trending Market Intelligence /marketintelligence/en/news-insights/trending/iqtj_hwnhzqemsuj7lemfa2 content esgSubNav
In This List

Profound Medical's device to treat uterine tumors approved by Chinese regulator

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Profound Medical's device to treat uterine tumors approved by Chinese regulator

Profound Medical Corp. said the China Food and Drug Administration approved its device Sonalleve for the noninvasive treatment of uterine fibroids.

Uterine fibroids are the most common noncancerous tumors of the female reproductive tract in women, according to the company.

The Canadian device-maker said the product enables more precise and incision-free removal of diseased tissue.

Profound Medical acquired the Sonalleve MR-HIFU business from Royal Philips in 2017.